C07C 275/40
Being further substituted by nitrogen atoms not being part of nitro or
Official title: being further substituted by nitrogen atoms not being part of nitro or nitroso groups
C07C275/40 (Being further substituted by nitrogen atoms not being part of nitro or) appears on 363 US grants and 269 published applications in this corpus.
Search patents in C07C- Granted patents
- 363
- Published applications
- 269
- Assignees
- 217
- Inventors
- 1,102
- Latest grant
- 5 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 6 | 0 |
| 1977 | 8 | 0 |
| 1978 | 2 | 0 |
| 1979 | 3 | 0 |
| 1980 | 5 | 0 |
| 1981 | 8 | 0 |
| 1982 | 2 | 0 |
| 1983 | 2 | 0 |
| 1984 | 7 | 0 |
| 1985 | 7 | 0 |
| 1986 | 1 | 0 |
| 1987 | 5 | 0 |
| 1988 | 7 | 0 |
| 1989 | 7 | 0 |
| 1990 | 6 | 0 |
| 1991 | 5 | 0 |
| 1992 | 5 | 0 |
| 1993 | 3 | 0 |
| 1994 | 3 | 0 |
| 1995 | 8 | 0 |
| 1996 | 7 | 0 |
| 1997 | 8 | 0 |
| 1998 | 17 | 0 |
| 1999 | 9 | 0 |
| 2000 | 9 | 0 |
| 2001 | 12 | 9 |
| 2002 | 18 | 18 |
| 2003 | 9 | 25 |
| 2004 | 22 | 16 |
| 2005 | 8 | 13 |
| 2006 | 7 | 9 |
| 2007 | 7 | 11 |
| 2008 | 9 | 13 |
| 2009 | 8 | 13 |
| 2010 | 6 | 7 |
| 2011 | 9 | 12 |
| 2012 | 10 | 10 |
| 2013 | 4 | 9 |
| 2014 | 14 | 11 |
| 2015 | 9 | 8 |
| 2016 | 11 | 12 |
| 2017 | 4 | 17 |
| 2018 | 9 | 10 |
| 2019 | 9 | 3 |
| 2020 | 6 | 8 |
| 2021 | 6 | 8 |
| 2022 | 5 | 4 |
| 2023 | 5 | 9 |
| 2024 | 3 | 6 |
| 2025 | 2 | 2 |
| 2026 | 1 | 6 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Urea derivatives and their use as curatives and curative accelerators for resin systems5 May 2026US 12,617,753 B2Hexcel Composites Limited
- Cathepsin inhibitors29 Jul 2025US 12,371,400 B2Academisch Ziekenhuis Leiden (H.O.D.N. Lumc)
- Combined modalities for nucleosides and/or NADPH oxidase (NOX) inhibitors as myeloid-specific antiviral agents4 Mar 2025US 12,239,655 B2Emory University
- Compositions and methods for the treatment of cancer24 Sep 2024US 12,098,117 B2Duke University
- Therapeutic compounds as inhibitors of the orexin-1 receptor2 Jul 2024US 12,024,509 B2C4X Discovery Limited
- Protease inhibitors for treating or preventing coronavirus infection23 Jul 2026US 2026/0209180 A1Merck Sharp & Dohme Corp.
- Novel inhibitors of dna damage responses for cancer therapy23 Jul 2026US 2026/0209193 A1The Regents of the University of California
- Staphylococcus aureus pbp4 inhibitors and method of use7 May 2026US 2026/0124213 A1University of Notre Dame du Lac
- Covalent, chemogenetic activators for k2p potassium channels and uses thereof9 Apr 2026US 2026/0098008 A1The Regents of the University of California
- N-(benzhydryl)cycloalkylcarboxamide derivatives as inhibitors of glycogen synthase 1 (gys1) and methods of use thereof26 Mar 2026US 2026/0085034 A1Maze Therapeutics, Inc.
Most cited
By later US patents
- Tetraaryl benzidines128US 5,639,914 AHodogaya Chemical Co., Ltd. · 1997
- Amine compound and electro-luminescence device comprising same122US 5,707,747 AHodogaya Chemical Co., Ltd. · 1998
- Cell differentiation inducer110US 6,174,905 B1Mitsui Chemicals, Inc. · 2001
- Guanylhydrazones and their use to treat inflammatory conditions94US 5,854,289 AThe Picower Institute for Medical Research · 1998
- IL-8 receptor antagonists92US 5,886,044 ASmithKline Beecham Corporation · 1999